ARVN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AR

Mkt Cap

$455.3M

Volume

617.47K

Next Earnings

November 4th

Loading chart

AR

ARVNArvinas, Inc

ARVN

Pay with—

Available Balance0.00

AR

Mkt Cap

$468.2M

Volume

617.47K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

KRYS Reports Positive Early Data for KB113 in Gorlin SyndromeKrystal Biotech announced positive pilot study results for KB113, an investigational immunotherapy for basal cell carcinomas in Gorlin syndrome patients. The treatment showed clinical regression in 83.1% of assessed lesions across three patients, including 85.1% regression in non-injected lesions suggesting systemic immune activity. KB113 was well tolerated, and the company has begun FDA discussions on advanced clinical development.Zacks Investment Research · Oct 16, 2026

Reasons Why Investors Should Consider Betting on Arvinas StockArvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027.Zacks Investment Research · Oct 13, 2026

TGTX Stock Rises 60% in 6 Months: Here's What You Should KnowTG Therapeutics (TGTX) shares have risen 59.9% over six months, driven by robust sales of its marketed drug Briumvi for relapsing multiple sclerosis. Briumvi sales grew 69% to $437.1 million in the first half of 2026, prompting the company to raise its full-year revenue guidance to approximately $950 million. The company is expanding Briumvi's potential through phase II studies for schizophrenia and myasthenia gravis, and developing a subcutaneous formulation expected to deliver data by end of 2026 or Q1 2027.Zacks Investment Research · Oct 13, 2026

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver DiseasesMirum Pharmaceuticals announced that its Phase III EXPAND study met the primary endpoint for Livmarli (maralixibat) in treating cholestatic pruritus in patients with ultra-rare cholestatic liver diseases. Livmarli showed a 1.81-point improvement in itch severity versus 0.83 for placebo and achieved a 69% reduction in serum bile acids. The company plans to submit a supplemental new drug application to the FDA in the first half of 2027. Livmarli sales have grown 50.2% year-over-year in the first half of 2026, reaching $242.5 million.Zacks Investment Research · Oct 13, 2026

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s DiseaseArvinas presented Phase 1 clinical trial data for ARV-102, a PROTAC LRRK2 degrader, showing dose-dependent improvements in oculomotor function and correlations between LRRK2 reduction and improvements in biomarkers related to endolysosomal function, neuroinflammation, and synaptic integrity in Parkinson's disease patients. The findings support continued clinical evaluation of ARV-102 for neurodegenerative diseases associated with LRRK2 dysregulation.GlobeNewswire Inc. · Oct 7, 2026

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology CandidateArvinas announced the first patient dosing in a Phase 1/2 clinical trial of ARV-6723, an oral PROTAC designed to degrade HPK1 for advanced solid tumors. The drug is Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the US. Preclinical data showed potent HPK1 degradation, enhanced immune activity, and antitumor effects as monotherapy and in combination with anti-PD-1 therapy, including activity in anti-PD-1-resistant models.GlobeNewswire Inc. · Sep 28, 2026

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s DiseaseArvinas announced it has joined The Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange (LITE) program and Parkinson's Precision Medicine Initiative (PPMI) to advance ARV-102, its investigational PROTAC drug targeting LRRK2 for treating Parkinson's disease and progressive supranuclear palsy. The company plans to initiate Phase 1b and potentially Phase 2 registrational trials in PSP patients in the second half of 2026.GlobeNewswire Inc. · Jun 4, 2026

ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsightThe ESR1-mutated metastatic breast cancer market is projected to grow at 9.6% CAGR through 2036, driven by rising prevalence of endocrine-resistant HR-positive/HER2-negative breast cancer and adoption of precision oncology. Novel oral SERDs and targeted agents from major pharmaceutical companies are reshaping the treatment landscape. The market was valued at USD 1.5 billion in 2025, with the US representing the largest market share. Recent FDA approvals include VEPPANU (vepdegestrant), the first PROTAC therapy, while several emerging therapies are in clinical development.GlobeNewswire Inc. · May 20, 2026

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, PfizerRigel Pharmaceuticals announced an exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an oral PROTAC drug for ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. Rigel will contribute up to $40 million toward development over four years and pursue U.S. and global commercialization rights. The drug received FDA approval in May 2026, showing a 43% reduction in disease progression or death risk compared to fulvestrant in the Phase 3 VERITAC-2 trial.Benzinga · May 12, 2026

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026Arvinas, Inc. announced FDA approval of VEPPANU (vepdegestrant), the first-and-only FDA-approved PROTAC protein degrader, for treating estrogen receptor-positive advanced breast cancer with ESR1 mutations. The approval came ahead of the FDA-assigned PDUFA date of June 5, 2026. The company also reported positive Phase 1 data for ARV-102 showing greater than 50% LRRK2 degradation in Parkinson's disease patients.GlobeNewswire Inc. · May 5, 2026

to start trading

AR

ARVNArvinas, Inc

ARVN

Pay with—

Available Balance0.00

Your PositionYou don't own any ARVN yet.

Related Tickers

Earnings